An economic model of long-term use of celecoxib in patients with osteoarthritis

BACKGROUND: Previous evaluations of the cost-effectiveness of the cyclooxygenase-2 selective inhibitor celecoxib (Celebrex, Pfizer Inc, USA) have produced conflicting results. The recent controversy over the cardiovascular (CV) risks of rofecoxib and other coxibs has renewed interest in the economic...

Descripción completa

Detalles Bibliográficos
Autores principales: Loyd, Michael, Rublee, Dale, Jacobs, Philip
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1925103/
https://www.ncbi.nlm.nih.gov/pubmed/17610716
http://dx.doi.org/10.1186/1471-230X-7-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1925103/
https://www.ncbi.nlm.nih.gov/pubmed/17610716
http://dx.doi.org/10.1186/1471-230X-7-25

Ejemplares similares